Table 1.
Age | Symptoms | Virus | AFP | Diagnosis2 | Type | Therapy | Time1 (Mon) | Status | Ref. | |
1 | 43 | Abdominal swelling | HBV | NA | Autopsy2 | Combined | Adriamycin, 5-FU | 26 | Death | Barsky et al[8] |
2 | 69 | Abdominal pain | HBV | NA | FNA2 | Combined | NA | NA | NA | Artopoulos et al[10] |
3 | 63 | Abdominal pain, jaundice | NA | NA | Resection | Combined | NA | 1 | Death(bleeding spesis) | Vora et al[11] |
4 | 72 | NA | HCV | 13.6 | Resection, LND | Collision | NA | NA | NA | Ishida et al[2] |
5 | 71 | NA | HCV | 20.7, 479.1 | Resection | Combined (intermingled) | NA | 5 | NA | Yamaguchi et al[6] |
6 | 50 | NA | HCV | 1191 | Core biopsy, then Resection | Collision | TACE, cisplatin, doxorubicin, thalidomide and Avastin | 16 | alive | Garcia et al[1] |
7 | 65 | Epigastric pain | HBV | Normal | Resection, LND | Combined | NA | 12 | Death | Yang et al[7] |
8 | 68 | NA | HBV | 1191 | Resection | Collision | Cisplatin, etoposide | 28 | Alive | Tazi et al[4] |
9 | 76 | Echo-detected | HCV | 281.4, 14.9, 2632 (after TACE) | TACE, resection | Combined NE with sarcomatous change | TACE, epirubicin lipiodol | 17 | Death | Nakanishi et al[5] |
10 | 51 | Abdominal pain | HCV | NA | Biopsy | Combined | NA | 1 | Death | Hammedi et al[12] |
11 | 56 | Abdominal distension | NA | 70 | Resection | Combined | NA | 6 | Alive | Aboelenen et al[13] |
12 | 72 | No symptoms | HCV | 24.8 | Resection | Collision | Cisplatin, etoposide | 2 | Death | Nishino et al[14] |
13 | 72 | No symptoms | HCV | 3.8 | Resection | Collision | Cisplatin, etoposide | 10 | Alive | Choi et al[15] |
14 | 76 | NA | NA | 49.2 | Resection | Collision | Cisplatin | NA | Alive | Baker et al[9] |
15 | 71 | NA | HCV | 4791 | Resection | Combined | NA | 8.6 | Death | Nomura et al[16] |
16 | 71 | NA | HCV | 10.3 | Resection | Collision | NA | 2.6 | Death | Nomura et al[16] |
17 | 58 | NA | HBV | 176.4 | RFA, Resection | Combined | NA | 19.7 | Alive | Nomura et al[16] |
18 | 50 | NA | HBV | 473.7 | Resection | Combined | NA | 19.5 | Alive | Nomura et al[16] |
19 | 63 | NA | HCV | 2276 | Resection | Combined | NA | 24 | Alive | Nomura et al[16] |
20 | 65 | Abdominal discomfort | HCV | 400.06 | Resection | Collision | NA | 1.3 | Death | Liu et al[17] |
21 | 70 | Solid mass | HCV | 3.7 | TAE and TPE, Resection | Collision and combined | NA | 3 | Death | Okumura et al[18] |
22 | 56 | Incidental | NA | 2.8 | Liver transplantation (Resection specimen) | Collision | NA | 10 | Alive | Yılmaz et al[3] |
23 | 79 | Abnormal liver function | NA | 3231.8 | Resection | Combined | NA | 4 | Death | Ikeda et al[19] |
24 | 84 | Higher AFP values | NA | 399 | Laparoscopic resection | Combined | NA | 9 | Alive | Nakano et al[20] |
25 | 48 | Incidental | HBV | 29.91 | RFA, TACE, RFA, Resection | Collision | Chemotherapy | 40 | Death (sepsis) | Our study |
Time in months (since diagnosis).
Diagnosis: All are hepatocellular carcinoma (HCC) coexisting with neuroendocrine tumors except the two (2): HCC with carcinoid. NA: None, or not included or not available; HBV: Hepatitis B virus; HCV: Hepatitis C virus; AFP: Alpha-fetoprotein (ng/mL); FNA: Fine needle aspiration; 5-FU: 5-fluorouracil; TACE: Transarterial chemoembolization; TAE: Transarterial embolization; TPE: transportal vein embolization.